It confirms [59] that CRHR2 receptor antagonists (Astressin2B) can block the TLR4/NF-κB signaling pathway in DSS-induced colitis mice to reduce the levels of TNF-α, IL-6, and IL-1β in serum, thereby protecting the colon mucosa. The gene discussed is TNF; the disease is colitis.